Dermatology

New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.

Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.

An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.

New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

International investigators observe differing levels of severe COVID-19 risk for patients with atopic dermatitis, dependent on their current therapy.

Data from the phase 3 TRuE-V clinical program show the topical JAK inhibitor provided substantial repigmentation to more than half of treated patients.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

A Perelman School of Medicine assessment of biopsy rates support previous findings showing that dermatologists are less confident making psoriasis diagnoses in patients with darker skin color.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.

Investigators believe these results may aid shared decision-making between clinicians and patients.

Internalized skin bias also appeared to mediate the associations of depression and anxiety related to health-related quality of life.

An analysis of the EUROSTAD study found that the median duration of treatment with the biologic was 14 months.

The FDA asked the company to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.

Investigators examined data on abrocitinib from the JADE REGIMEN study.

Itch intensity was highest at bedtime compared to all other time periods of the day.

Patients with allergic asthma could often have no clinical history of atopic dermatitis.

The most common burden of disease were itching, dry or rough skin, and cracked skin.

Those who were breastfed for less than 4 months also had lower risks of developing atopic diseases.

the high prevalence of the condition in middle-age and elderly populations has led to frequent updates on the long-term efficacy of current therapies and new investigational agents.

Telemedicine use has become more prevalent during the ongoing COVID-19 pandemic. However, there is limited data on patient satisfaction with tele-dermatology

Prior to the ISS, there was no known scale to measure ichthyosis severity across the entire body.